Product Description
Mechanisms of Action: Voltage-Gated Sodium Channel Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Chile | China | Colombia | Cyprus | France | Germany | Greece | Hong Kong | India | Indonesia | Ireland | Italy | Lithuania | Malaysia | Morocco | Netherlands | Pakistan | Philippines | Slovenia | Spain | Sweden | Taiwan | Thailand | United Arab Emirates | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Colgate Palmolive
Company Location: NEW YORK NY 10022
Company CEO: Noel R. Wallace
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Dental Plaque
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CRO-2022-10-PG-MER-MW-JG | P3 |
Completed |
Dental Plaque |
2024-03-06 |
38% |